戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 blocked by inhibition of HIF-1 signaling via echinomycin.
2 sed to examine the conformational effects of echinomycin, a DNA bis-intercalating antibiotic, on line
3                                              Echinomycin, a ligand with a bisintercalative binding mo
4                                              Echinomycin, a member of the quinoxaline family of antib
5 mplexes containing different drugs including echinomycin, actinomycin-D, ethidium bromide, Hoechst 33
6 tranded DNA is not inhibited indicating that echinomycin acts by interacting with the DNA and not the
7                                              Echinomycin, an inhibitor of hypoxia-inducible factor (H
8 ts that direct molecular recognition between echinomycin and DNA, mediated by hydrogen bonding and va
9 respectively, L1210 cell line) comparable to echinomycin and one analogue, which bears the luzopeptin
10 us choshinensis conferred resistance against echinomycin and other quinomycin antibiotics, including
11      Both inhibition of HIF-1 DNA binding by echinomycin and RNA interference of HIF-1alpha synthesis
12 of anticancer depsipeptides thiocoraline and echinomycin, and by mutants of these domains, for which
13 mportantly, in mice with complete remission, echinomycin appeared to completely eliminate LICs becaus
14 portantly, in X.laevis embryos injected with echinomycin at the two-cell stage the drug specifically
15  which the 2-amino group that is crucial for echinomycin binding has been added or removed, respectiv
16    The structural perturbations induced when echinomycin binds to closed circular duplex pBR322 DNA w
17 available among the different DNA fragments; echinomycin binds to TpD sites much more tightly than to
18                                          The echinomycin biosynthetic gene cluster in Streptomyces la
19 insertion domain allows Ecm16 to distinguish echinomycin-bound DNA from normal DNA and link substrate
20  high-affinity bisintercalation analogous to echinomycin, but with little or no perceptible sequence
21 poxia-inducible factor (HIF)1alpha inhibitor echinomycin can be used to treat relapsed AML without af
22                In the presence of increasing echinomycin concentration, the plasmid can be seen to pr
23                                 We show that echinomycin cured 40% to 60% of mice transplanted with r
24         Pharmacologic targeting of HIF-1a by echinomycin delivered via nanoliposomes can efficiently
25                             The oxidation of echinomycin/DNA complexes containing duplexes with diffe
26 at a combination of actinomycin D (ActD) and echinomycin (Echi), can interact in novel ways with nati
27 d patient-derived AML cells, we tested a new echinomycin formulation with longer half-life and signif
28 , we tested efficacy of HIF-1alpha inhibitor echinomycin in TP53-mutated AML samples in vitro and in
29                   Evidence is presented that echinomycin interferes with chromatin decondensation, nu
30                                              Echinomycin is a natural product DNA bisintercalator ant
31                                    Liposomal echinomycin is more potent and effective in inhibiting W
32                                     About 66 echinomycin molecules are able to bind to each fragment,
33  + daunorubicin enriched for AML stem cells, echinomycin nearly eliminated this population.
34 One of the most potent compounds identified, echinomycin (NSC-13502), a small-molecule known to bind
35                               In the case of echinomycin only one purine 2-amino group is required fo
36                         HIF-1a inhibition by echinomycin or small interfering RNA silencing prevented
37 duplexes complexed with the DNA binding drug echinomycin result in increased occupancy of the (w)cWH
38                                              Echinomycin selectively eliminated CD34(+)CD38(-) AML ce
39 t in a mouse model of relapsed AML, low-dose echinomycin selectively targets LICs and spares normal h
40 rcalating antibiotics (e.g., triostine A and echinomycin), the detailed interactions between those tw
41 ve examined the binding of actinomycin D and echinomycin to artificial DNA molecules asymmetrically s
42                  Here we study the effect of echinomycin upon DNA replication using egg extracts and
43                                              Echinomycin was broadly effective against a panel of pri
44                                              Echinomycin was broadly effective against xenografts fro
45          To test the therapeutic efficacy of echinomycin, we established a xenograft model of TP53-mu
46 lex, free and in complex with the antibiotic echinomycin, which features two central adenine-thymine
47                       For the association of echinomycin with DNA, we found DeltaG degrees = -7.6 kca
48 lative interaction of the peptide antibiotic echinomycin with DNA.